Brain natriuretic peptide transdermal - Zosano Pharma

Drug Profile

Brain natriuretic peptide transdermal - Zosano Pharma

Alternative Names: B-type natriuretic peptide transdermal - Zosano Pharma; BNP transdermal - Zosano Pharma

Latest Information Update: 02 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zosano Pharma
  • Class Heart failure therapies; Natriuretic peptides; Nerve tissue proteins
  • Mechanism of Action Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 31 Aug 2016 Discontinued - Phase-I for Heart failure (Transdermal)
  • 29 Sep 2015 Phase-I clinical trials in Heart failure (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top